CENTRE HOSPITALIER UNIVERSITAIRE DE LIEGE

Their core work

CHU Liège is a major Belgian university hospital that combines clinical care with active research in neuroscience, inflammatory diseases, and AI-driven diagnostics. Within EU projects, they contribute clinical expertise, patient cohorts, and real-world hospital data — particularly in brain research (as a long-standing Human Brain Project partner), immune-mediated diseases, and medical imaging AI. Their recent work focuses on deploying artificial intelligence tools in hospital settings for diagnosis, cancer survivorship, and pandemic response, positioning them as a clinical validation site where research meets patient care.

What they specialise in

How they've shifted over time

In the early period (2015-2018), CHU Liège focused heavily on neuroscience through the Human Brain Project and on inflammatory bowel disease research through BIOCYCLE, their sole coordinated project. From 2019 onward, their portfolio shifted decisively toward AI-powered clinical applications — COVID diagnostics, cancer survivorship, precision medicine, and smart hospital systems. This transition reflects a hospital moving from contributing clinical data to basic science toward actively integrating AI and digital tools into frontline patient care.

CHU Liège is rapidly building capacity in hospital-deployed AI, making them a strong clinical validation partner for any project needing real-world testing of diagnostic or decision-support tools.

How they like to work

CHU Liège primarily participates as a partner or third party rather than leading consortia — they coordinated only 1 of 13 projects. Their five third-party roles (all within the Human Brain Project ecosystem) suggest they provide specialized clinical or data contributions to large flagship initiatives. With 275 unique partners across 30 countries, they operate within very large consortia and bring clinical grounding to research-heavy collaborations rather than driving project design.

With 275 consortium partners across 30 countries, CHU Liège has one of the broadest networks among Belgian clinical institutions, largely built through the massive Human Brain Project consortia and multi-partner health AI projects. Their reach spans all of Europe with no strong geographic bias.

What sets them apart

CHU Liège occupies a rare position as a large university hospital that bridges fundamental neuroscience research and applied clinical AI — few hospitals have been embedded in a flagship like the Human Brain Project while simultaneously running multiple AI diagnostics pilots. For consortium builders, they offer what most research labs cannot: real patient populations, clinical workflows, hospital IT infrastructure, and regulatory context for validating health technologies in practice. Their Crohn's disease coordination experience also shows they can lead focused clinical studies, not just contribute data.

Highlights from their portfolio

• BIOCYCLE
  Their only coordinated project — an ERC-funded study on optimizing Crohn's disease treatment cycles, demonstrating independent research leadership in gastroenterology.
• DRAGON
  Largest single funding allocation (EUR 506K) focused on AI-enhanced pandemic diagnosis and precision medicine, reflecting their pivot to clinical AI.
• HBP SGA3
  Sustained involvement across all three phases of the Human Brain Project (2016-2023) shows deep integration in Europe's largest neuroscience initiative.